Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Oct 05, 2010 12:42pm
380 Views
Post# 17530351

Can Haywood Lead us to the Promise Land?

Can Haywood Lead us to the Promise Land?Terry:

[S] Bottom line is as BRD:

1. Reduces every OZ of the hedge,

2. Buys back every (converted) warrant and,

3. Retires every $ dollar of outstanding debt,

BRD as an "investment" is proportionately increased.

I always look to the Globe & Mail or BNN for their take on the reason(s) that the POG is doing so well today. John Embry made this call before? i.e. POG will rise as the Global stimuli are in fact inflationary:

Taken from the G & M:

"IMF report clouds outlook

A new report from the International Monetary Fund further clouds the outlook for the global economy as central banks debate the need for more stimulus, politicians quarrel over whether to boost spending or cut deficits and investors drive the price of gold to record levels in a bid for safety.


Strain on the financial system has increased over the past six months, led by persistent worries over sovereign debt and a growing concern that banks lack the capital to operate effectively without government support, the IMF said, Globe and Mail Washington correspondent Kevin Carmichael writes.


“The global financial system is still in a period of significant uncertainty and remains the Achilles’ heel of the economic recovery,” the IMF said in its biannual Global Financial System Review, released today in Washington."

GLTAL-GLAP
Cheers
Stanley

Bullboard Posts